Vitaeris

Share on: 
Website: Vitaeris
Description: 

Vitaeris is dedicated to the development of a novel investigational approach to address antibody mediated rejection. Antibody mediated rejection has been recognized as the principal cause of late graft loss in solid organ transplant recipients. Our focus is on clazakizumab, a potent humanized monoclonal antibody targeting the cytokine interleukin-6 (IL-6).

Location(s): 
Vancouver BC
Canada